drugset
drugset / Trial / NCT05463848

Surgical Pembro +/- Olaparib w TMZ for rGBM

NCT05463848 ↗

Phase 2 Recruiting 78 enrolled L. Nicolas Gonzalez Castro, MD, PhD Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: * Pembrolizumab * Olaparib * Temozolomide (Temodar)

Timeline

Start
2022-10-21
Primary completion
2026-08-01
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule — Oral
Subject Pembrolizumab Monoclonal antibody — Intravenous
Subject Temozolomide Small molecule — Oral

Indications

glioblastoma